Prior to starting the webinar

- Please make sure you have audio AND web features
- For audio, dial 866-740-1260
  - Enter access code 8223833
- For video, go to www.readytalk.com
  - Enter access code 8223833
- To obtain materials for today’s webinar, register at www.pharmacogenomics.ucsd.edu
- Please turn off cell phones, pagers, and program your phone to divert calls to voicemail
- You may use the “Chat” function to raise questions during the presentation. You may also ask questions directly during the Q&A session. Questions will be answered during the Q & A session.

Disclaimer

This presentation was supported by Grant Number IU38GD000070 from Centers for Disease Control and Prevention (CDC). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC.

The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should seek the advice of their physicians, pharmacists, or other qualified health providers with any questions they may have regarding a medical condition or a medication.

Train-the-Trainer Agenda

1. Introduction
   - Objective of PharmGenEd™ program
   - Shared curriculum and format
   - Introduction of author
2. Review of educational content for selected therapeutic area
3. Future webinar dates
   - Program implementation
   - Other therapeutic areas
4. Contact information
5. Survey instruments
   - Post training survey for trainers
6. Question & Answer (Q & A) session
Overall Objective of PharmGenEd™ Program

- The "Pharmacogenomics Education Program: Bridging the Gap between Science and Practice" (PharmGenEd™) is an evidence-based pharmacogenomics education program designed for pharmacists and physicians, pharmacy and medical students, and other healthcare professionals.

- The overall objective of the PharmGenEd™ program is to increase awareness about current knowledge of the validity and utility of pharmacogenomic tests and the potential implications of benefits and harms from use of the tests.

Shared Curriculum

- Educational Materials (each 1 hour)
  - Asthma
  - Cardiology I (warfarin & statins)
  - Cardiology II (clopidogrel & beta blockers)
  - Concepts and clinical applications
  - Economic issues
  - Oncology I (solid tumors)
  - Oncology II (hematologic malignancies)
  - Psychiatry I (depression)
  - Psychiatry II (antipsychotics)

- Future webinar dates for these sessions will be provided later

Therapeutic Area Discussion

- Format
  - Patient case
  - Gene/Allele of interest
  - Functional effect
  - Population prevalence
  - Clinical relevance (dosing/selection, efficacy, and toxicity)
  - Genomic test and testing recommendation
  - Patient case summary

Author

Vicki L. Ellingrod, PharmD, BCPP, FCCP
Associate Professor
University of Michigan, College of Pharmacy
Learning Objectives

• Upon completion of this program, participants will be able to:
  – Identify specific drug therapies in which pharmacogenomic testing can be applied in the clinical setting
  – Summarize evidence-based recommendations for pharmacogenomic testing
  – Using patient case scenarios, formulate a plan for pharmacogenomics testing based upon available scientific evidence

Antidepressant Medications

• Primary Indications
  – Major depressive disorders (MDD), obsessive-compulsive disorder (OCD), and anxiety disorders
• Pharmacogenomic studies
  – Response in major depressive disorders
  – Side effects
    • Medication intolerance, sexual dysfunction, gastrointestinal (nausea and vomiting)

Patient Case

• 25 year old African-American female student who was referred to the clinic by her faculty advisor after requesting to leave school
  – CC: “I’m sad. I can’t do it anymore.”
  – Vitals
    • Weight: 68 kg, Height: 5’8”
    • BP: 108/70, HR: 68
  – HPI (over 3 months): Depressed mood, loss of interest in usual activities, low energy, poor sleep, past thoughts about killing herself but no current suicidal ideation
  – Diagnosis: MDD, Hamilton Rating Scale for Depression (HAM-D) score at clinic visit: 20

Davidson 2010, Schosser et al 2009

Furukawa 2010, Hamilton 1960
**Patient Case Treatment**

- **Family History:**
  - Mother: Currently being treated for depression (medication name unknown)
    - Many people in her family are “sensitive” to medications
  - After 8 weeks of treatment with paroxetine 20 mg/day
    - patient is doing much better (HAM-D = 12)
    - she has significant sexual dysfunction (anorgasmia) and asks if there is anything that can be done about this


**Patient Case (continued)**

- Since she has done so well on paroxetine, patient states that she DOES NOT want to discontinue paroxetine.
- Bupropion 150mg/day is used for augmentation of paroxetine and sexual dysfunction
- After 3 weeks of treatment, she complains that her sexual dysfunction has become much worse along with significant nausea. She also feels that her depressive symptoms are getting worse.

*Safarinejad 2010, Teter et al 2008*

**Patient Case (continued)**

- Nine weeks after starting treatment, paroxetine and bupropion are discontinued
- So why would patient’s sexual dysfunction and nausea get worse?
- The decision is made to start venlafaxine since it has a different mechanism of action

**Patient Case (continued)**

- Six weeks after starting venlafaxine, there is no improvement (HAMD = 15)
  - Patient is very frustrated and she is genotyped for the CYP2D6 enzyme
  - Test results show that patient is an intermediate metabolizer
- Venlafaxine is discontinued and patient is started on citalopram 20 mg QD
  - Patient eventually goes into remission
  - There is no recurrence of sexual dysfunction
Patient Case Questions

• Questions related to this case
  – Given that we now know she is a CYP2D6 intermediate metabolizer, does this explain anything in her past treatment?
  – If we have had this information at the beginning of treatment, how might it have changed practice and the patient’s response?

De Leon 2007

Treatment of Depression

Antidepressant Classes:
1. Selective Serotonin Reuptake Inhibitors (SSRI)
2. Serotonin Norepinephrine Reuptake Inhibitors (SNRI)
3. Tricyclic Antidepressants (TCA)
4. Monoamine Oxidase Inhibitors (MAOI)
5. Miscellaneous Agents: Trazodone, Nefazodone, Mirtazapine, and Bupropion

Teter et al 2008

Treatment of Depression

• First line treatment of MDD
  – Stage 0: Patient assessment and discussion of options including non-pharmacologic treatment
  – Stage 1: SSRI, bupropion, mirtazapine, SNRI as monotherapy
  – Stage 1: Partial Response – augment with additional agent
  – Stage 2: Non response – switch to a different class of antidepressant

TMAP 2010

Pharmacogenomics of Antidepressants

• Pharmacodynamic Effects
  – Variants associated with response are often associated with the pharmacology of antidepressants
    • Variants within the serotonin neurotransmitter system (receptors or transporters)
• Pharmacokinetic Effects
  – Variants associated with side effects are often associated with the metabolism of antidepressants
    • Variants within the cytochrome P450 system or drug transporter

**Antidepressant Pharmacology**

- Inhibit serotonin (5-HT) reuptake via serotonin transporter antagonism
  - All SSRIs and SNRIs, most TCAs
- Block norepinephrine (NE) reuptake
  - All TCAs and SNRIs
- Block dopamine (DA) reuptake
  - *Weak reuptake of bupropion.....also sertraline*
- Block NE, 5-HT, DA metabolic pathways
  - MAOIs
- Block postsynaptic 5-HT/NE receptors
  - Mirtazapine, nefazodone, trazodone

**Pharmacodynamic Candidates**

- Antidepressants have antagonistic effects at other receptors
  - Serotonin 2 and 3 (HTR2 and HTR3) receptors
  - Alpha 1 and 2 (α1 and α2) receptors
  - Histamine 1 (H1) receptors
  - Cholinergic (Ach) receptors
- Antagonism at these receptors may be associated with response and side effects

**Pharmacodynamic Candidates**

- Neurotransmitter systems
  - Serotonin
- Other miscellaneous growth factors and enzymes
  - Tryptophan hydroxylase 1 (TPH1)
  - Monoamine oxidase (MAO)
  - G-protein β-3 subunit (GNB3)
  - Brain-derived neurotrophic factor (BDNF)

**Response in Depression**

- Gene/Allele
  - Serotonin Transporter (*SLC6A4, 5HTTLPR, 17q11.1-q12*)
    - 44 base pair insertion deletion that may involve *SLC6A4* expression – results in a long (l) and short (s) allele
    - Variable number of tandem repeats (VNTR) within intron 2 (STIN2)
      - May contain 9, 10 or 12 copies of 16-17 bp repeat

---

Copyright ©2010 Regents of the University of California. All rights reserved.
Response in Depression

• Gene/Allele
  – Serotonin-5HT1A receptor gene (HTR1A) (9q11.2-13)
    • -1019C/G (rs6295)
    • For the HTR1A variants, the G allele results in reduced serotonergic neurotransmission
  – Serotonin-5HT2A receptor gene (HTR2A) (13q14-21)
    • C102T (rs6313)
    • -1438A/G (rs6311)
    • For the HTR2A variants, these variants are in complete linkage disequilibrium


Response in Depression

• Gene/Allele
  – Serotonin Biosynthesis
    • Tryptophan Hydroxylase 1 (TPH1) (11p15.3-p14)
      • 218 A/C
      • 779 A/C
    • Tryptophan Hydroxylase 2 (TPH2) (12q21.1)
      • 1463 G/A (Arg441His)
      • Arg447Pro
      • rs1843809, rs1386492, rs1487276

Response in Depression

• Gene/Allele
  – Monoamine Catabolism
    • Monoamine Oxidase A (MAOA) (Xp11.23)
      • VNTR
  – Serotonin Receptor Second Messenger
    • G protein β-3 subunit (GNB3) (12p13)
      • 825C/T (rs5443)
  – Growth Factors
    • Brain Derived Neurotrophic Factor (BDNF) (11p13)
      • Val66Met (rs6265)

Response in Depression

• Functional Effect
  – Serotonin Transporter (SLC6A4, 5HTTLPR, 17q11.1-q12)
    • L allele has twice the SLC6A4 expression than the s allele
  – STin2
    • May also affect SLC6A4 transcription and may be synergistic with 5-HTTLPR
• Population Prevalence
  – Serotonin Transporter (SLC6A4, 5HTTLPR, 17q11.1-q12)
    • The L allele is present in about 50-60% of the Caucasian population, and 30-40% in Asian populations
  – STin2
    • The 10 and 12 alleles has allele frequencies of 10-20% and 80-90% respectively within the Asian population


Copyright ©2010 Regents of the University of California. All rights reserved.
Response in Depression

- **Functional Effect**
  - Serotonin-5HT1A receptor gene (HTR1A) (5q11.2-13)
    - -1019C/G (rs6295)
      - The G allele results in reduced serotonergic neurotransmission
  - Serotonin-5HT2A receptor gene (HTR2A) (13q14-21)
    - C102T (rs6313)
    - -1438A/G (rs6311)
      - The -1438A allele has been associated with significantly increased promoter activity compared to the G allele. However, not all studies have confirmed this

- **Population Prevalence**
  - Serotonin-5HT1A receptor gene (HTR1A) (5q11.2-13)
    - Present in 50% of Caucasians and 21% of Asians
  - Serotonin-5HT2A receptor gene (HTR2A) (13q14-21)
    - Present in about 50% of the population.

Response in Depression

- **Functional Effect**
  - Tryptophan Hydroxylase 1 (TPH1) (11p15.3-p14)
    - 218 A/C
    - 779 A/C
  - Tryptophan Hydroxylase 2 (TPH2) (12q21.1)
    - 1463 G/A (Arg441His)
    - Arg447Pro
    - rs1843809, rs1386492, rs1488726

Response in Depression

- **Functional Effect**
  - Monoamine Catabolism
    - Monoamine Oxidase A (MAOA) (Xp11.23): VNTR 3.5 and 4 repeats have been found to be longer and are felt to be more functional than the 3 and 5 repeats
    - Serotonin Receptor Second Messenger
      - G protein β-3 subunit (GNB3) (12p13): 825 C/T (rs5443)
      - Brain Derived Neurotrophic Factor (BDNF) (11p13): Val66Met (rs6265)

- **Population Prevalence**
  - Monoamine Catabolism
    - VNTR: 3 repeats (36%), 3.5 repeats (9%), 4 repeats (56%), 5 repeats (<2%) in Caucasians
    - Serotonin Receptor Second Messenger
      - 825C/T (rs5443): The T allele is present in about 30-60% of Caucasian, Asian, and African populations

Antidepressant Pharmacokinetics

- Most of the antidepressants are metabolized by cytochrome P450 (CYP450) enzyme pathways
  - We have the most information about these pathways
    - Located primarily in the smooth endoplasmic reticulum in liver (also intestinal wall, kidney, nasal epithelium, lung, and brain)
### P450s and Drug Metabolism

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Fraction of Drug Metabolism</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP3A4</td>
<td>40-45%</td>
</tr>
<tr>
<td>CYP2D6</td>
<td>20-30%</td>
</tr>
<tr>
<td>CYP2C9</td>
<td>10%</td>
</tr>
<tr>
<td>CYP2C19</td>
<td>5%</td>
</tr>
<tr>
<td>CYP1A2</td>
<td>5%</td>
</tr>
<tr>
<td>CYP2E1</td>
<td>2-4%</td>
</tr>
<tr>
<td>CYP2A6</td>
<td>2-4%</td>
</tr>
<tr>
<td>CYP2C8</td>
<td>2%</td>
</tr>
</tbody>
</table>


### Antidepressant Substrates of P450s

<table>
<thead>
<tr>
<th>CYP1A2</th>
<th>CYP2B6</th>
<th>CYP2C19</th>
<th>CYP2D6</th>
<th>CYP3A4</th>
</tr>
</thead>
<tbody>
<tr>
<td>clomipramine</td>
<td>bupropion</td>
<td>clomipramine</td>
<td>all TCAs</td>
<td>Amitriptyline</td>
</tr>
<tr>
<td>imipramine</td>
<td>amitriptyline</td>
<td>atomoxetine</td>
<td>Clomipramine</td>
<td></td>
</tr>
<tr>
<td>amitriptyline</td>
<td>imipramine</td>
<td>paroxetine</td>
<td>imipramine</td>
<td></td>
</tr>
<tr>
<td>fluvoxamine</td>
<td>citalopram</td>
<td>venlafaxine</td>
<td>Trazodone</td>
<td></td>
</tr>
<tr>
<td>mirtazapine</td>
<td>duloxetine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>sertraline</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>fluoxetine</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>mirtazapine</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


### Antidepressant Inhibitors for CYP450

<table>
<thead>
<tr>
<th>Drug</th>
<th>CYP1A2</th>
<th>CYP2C9</th>
<th>CYP2C19</th>
<th>CYP2D6</th>
<th>CYP3A4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Citalopram</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>+/-</td>
<td>----</td>
</tr>
<tr>
<td>Escitalopram</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>+/-</td>
<td>----</td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>----</td>
<td>+/-</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>Fluvoxamine</td>
<td>+++</td>
<td>+</td>
<td>++</td>
<td>+/-</td>
<td>++</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>----</td>
<td>+/-</td>
<td>+/-</td>
<td>+++</td>
<td>----</td>
</tr>
<tr>
<td>Sertraline</td>
<td>----</td>
<td>+/-</td>
<td>+++</td>
<td>+</td>
<td>----</td>
</tr>
<tr>
<td>Nefazodone</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>++</td>
<td>----</td>
</tr>
<tr>
<td>Bupropion</td>
<td>----</td>
<td>----</td>
<td>++</td>
<td>----</td>
<td>----</td>
</tr>
<tr>
<td>Duloxetine</td>
<td>----</td>
<td>----</td>
<td>++</td>
<td>----</td>
<td>----</td>
</tr>
</tbody>
</table>

---- none or unknown, +/- slight, + low, ++ moderate, +++ potent

Adapted from Kotlyar et al 2005; Spina et al 2008

De Leon et al 2006

### Pharmacokinetic Candidates

- **Gene/Allele**
  - CYP2D6 gene is polymorphic
  - This means that it exists in different forms
- **Functional Effect**
  - These different forms result in different abilities to metabolize drugs that are substrates for this enzyme
Pharmacokinetic Candidates

• Functional Effect
  – Alterations within the CYP2D6 gene result in differences in metabolism
  – People can be classified as:
    • Ultra rapid metabolizers (UMs)
    • Rapid (or extensive) metabolizers (EMs)
    • Intermediate metabolizers (IMs)
    • Poor metabolizers (PMs)
  – There are over 78 different variants associated with CYP2D6 that result in metabolic differences

Pharmacokinetic Candidates

• Population Prevalence
  – Caucasians
    • 5-10% of Caucasians lack enzyme
    • CYP2D6 *1, *3, *4, *5, and *6 are the most common alleles for reduced metabolism
    • The *3 and *4 allele constitute ~75% of alleles responsible for the PM phenotype
  – Asian Populations
    • Most PM phenotypes due to CYP2D6 *10 allele
  – African Populations
    • Most PM phenotypes due to CYP2D6 *17 allele

Population Prevalence

<table>
<thead>
<tr>
<th>Major variant allele</th>
<th>Caucasians (%)</th>
<th>Asians (%)</th>
<th>African-Americans (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP2C9*2</td>
<td>8-12</td>
<td>&lt;3</td>
<td>&lt;3</td>
</tr>
<tr>
<td>CYP2C9*3</td>
<td>6-10</td>
<td>4-7</td>
<td>1-2</td>
</tr>
<tr>
<td>CYP2D6*4</td>
<td>12-21</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>CYP2D6*5</td>
<td>27</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>CYP2D6*10</td>
<td>1-2</td>
<td>51</td>
<td>6</td>
</tr>
<tr>
<td>CYP2D6*17</td>
<td>0</td>
<td>0</td>
<td>20-35</td>
</tr>
<tr>
<td>CYP2D6*41</td>
<td>8-10</td>
<td>0-2</td>
<td>11-14</td>
</tr>
<tr>
<td>CYP3A4*1B</td>
<td>4</td>
<td>0</td>
<td>67</td>
</tr>
<tr>
<td>CYP3A5*3</td>
<td>92-94</td>
<td>55-75</td>
<td>29-35</td>
</tr>
<tr>
<td>CYP1A2*1F</td>
<td>68</td>
<td>32</td>
<td>46</td>
</tr>
</tbody>
</table>

Clinical Relevance

• Efficacy
  – 5HTTLPR
    • Meta-analysis of 15 studies (1435 patients)
      – Remission (HAMD < 7)
      – Response (HAMD/MADRS ↓ by 50%)
      – 4 week response rate

• Toxicity
  – Antidepressant Intolerance
    • CYP2D6, HTR2A, serotonin transporter (5HTTLPR)
      – Murphy et al 2003
      – Murphy et al 2004
      – Murphy 2006
      – Hu et al 2007
  – SSRI-Associated Sexual Dysfunction
    • HTR2A, serotonin transporter (5HTTLPR)
      – Bishop et al 2006
      – Bishop et al 2009
  – SSRI-Associated Nausea and Vomiting
    • CYP2D6 and HTR2A
      – Suzuki et al 2006

Clinical Relevance

<table>
<thead>
<tr>
<th>OR (95% CI)</th>
<th>Total</th>
<th>Caucasian</th>
<th>Asian</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>L carriers vs ss</td>
<td>Il vs S carriers</td>
<td>L carriers vs ss</td>
</tr>
<tr>
<td>Remission</td>
<td>2.21* (1.5-3.21)</td>
<td>1.42 (0.9-2.04)</td>
<td>2.37* (1.56-3.6)</td>
</tr>
<tr>
<td>Response</td>
<td>1.20 (0.9-1.6)</td>
<td>2.01* (1.3-2.89)</td>
<td>1.53 (0.9-2.59)</td>
</tr>
<tr>
<td>4 week response</td>
<td>1.72* (1.2-2.47)</td>
<td>2.57* (1.7-3.88)</td>
<td>1.37 (0.6-2.88)</td>
</tr>
</tbody>
</table>

* = statistically significant
Clinical Relevance

• Toxicity
  – Inpatients treated for MDD (n = 365)
    • 30% received a CYP2D6 substrate
      – 13% of PMs and 36% of IMs treated with CYP2D6 substrate
    • DOTES (Dosage Record and Treatment Emergent Symptoms Scale)
      – PMs = 7.7 ± 4.7
      – Non PMs = 2.0 ± 3.4 (p = 0.007)
    • Clinical Global Impressions Scale
      – Response rate in IMs
      – Treated with CYP2D6 drugs = 7%
      – Treated with other medications = 25% (p = 0.017)

Laika et al 2009

Copyright ©2010 Regents of the University of California. All rights reserved.
Pharmacogenomic Test

- No FDA-approved pharmacogenomic test for pharmacodynamic targets
  - Available from selected private and academic laboratories
  - Reimbursement unclear
- There are several FDA-approved pharmacogenomic test for CYP2D6 (and CYP2C19)
  - Despite the availability of this test, it often does not get used clinically
  - Problems concerning the use of the these tests include cost and provider familiarity with test and results
  - Reimbursement may be obtained but coverage is not consistent

De Leon et al 2006

Testing Recommendation

- Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group Conclusion of literature review and meta-analysis
  - “There is a paucity of good-quality data addressing the questions of whether testing for CYP450 polymorphisms in adults entering SSRI treatment for non-psychotic depression leads to improvement in outcomes, or whether testing results are useful in medical, personal, or public health decision making”.

EGAPP 2007

Testing Recommendation

- Based on these guidelines, pharmacogenomic testing is not recommended for everyone.
- However, these guidelines do not preclude using pharmacogenomic testing in clinical practice.
- There may be situations in which pharmacogenomic testing may help to guide therapy decisions and prevent the occurrence of side effects and or non-response.


Case Summary

- As the case pointed out, knowing CYP2D6 genotype information before starting treatment may allow for greater success in treating depression due to the potential for early remission with personalized medicine regimens based on this information.

Kotlyar et al 2005
Summary

- Pharmacogenomic testing as it relates to the treatment of depression
  - Pharmacodynamic
    - Based on medication pharmacology and neurotransmitters related to depression pathophysiology
      - 5HTTLPR
  - Pharmacokinetic
    - Based on medication's absorption, metabolism, distribution, and excretion characteristics
      - CYP2D6

(53)

Summary

- Serotonin Transporter
  - Pharmacodynamic target of many antidepressants
    - 5HTTLPR
      - Also known as serotonin transporter promoter region (SERTPR)
      - Felt to explain about 15% of the variance seen in antidepressant response
      - Most studied and most consistent finding across all pharmacogenomic studies relating to antidepressant response
  - Other pharmacodynamic targets have been identified

(54)

Summary

- CYP2D6 is an isoenzyme that is responsible for the metabolism of up to 20% of all medications
  - Within psychiatry, most medications are metabolized by CYP2D6
  - For antidepressants, very few are not metabolized by CYP2D6 and many inhibit this enzyme

(55)

Summary

- Testing for CYP2D6 metabolic capability is commercially available
  - This test is not routinely used due to issues with prescriber familiarity, cost, and insurance reimbursement
    - A recently convened panel of experts (EGAPP) were unable to find data to support its use clinically
    - They emphasized the promise of CYP2D6 testing in major depressive disorder and advised that more research be done.
  - While CYP2D6 testing may be important for determining side effects to the antidepressants, there are many other pharmacodynamic targets that also need to be considered.
  - Antidepressant response is multi-factorial, with pharmacogenetics playing only one part

(56)
Acknowledgements

• Author
  Vicki L. Ellingrod, PharmD, BCPP, FCCP
  Associate Professor
  University of Michigan, College of Pharmacy

• Reviewers and Editorial Staff
  Primary Reviewer and Editor
    – Kelly C. Lee, PharmD, BCPP
  Reviewers and Associate Editors
    – Grace M. Kuo, PharmD, MPH
    – Sarah McBane, PharmD, CDE, BCPS
  Assistant Editors
    – Carine L. Hawley, MPH
    – Ashley To, BA

References

Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; Mar;3(2):229-43.


Copyright ©2010 Regents of the University of California. All rights reserved.

References


Murphy, G.M., Jr., et al., Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004; 61(11):1163-9.


References

Contact for TTT for Faculty
PharmGenEd™ Training for Health Professional Schools
Kelly C. Lee, PharmD, BCPP
Phone: 858-822-3462
Email: kellylee@ucsd.edu

General Questions about PharmGenEd™
pharmacogenomics@ucsd.edu

Principal Investigator and Program Director
Grace M. Kuo, PharmD, MPH
Phone: 858-822-7754
Email: kuoffice@ucsd.edu

PharmGenEd™ Team
• UCSD Faculty
  – Grace M. Kuo, PharmD, MPH (PI)
  – Kelly C. Lee, PharmD, BCPP
  – Joseph D. Ma, PharmD
  – James R. Halpert, PhD
  – Theodore Ganiats, MD
  – Philip E. Bourne, PhD
  – Palmer Taylor, PhD

• Consultants
  – Magnus Ingelman-Sundberg, PhD (Karolinska Institute, Sweden)
  – Karen S. Hudmon, DrPH, MS, RPh (Purdue University)

• Project Coordinator
  – Ashley To, BA

The program is 100% funded by the CDC (Grant Number IU58GD000070)
Webinar Dates
(all times are PST)

- **Oncology II: Hematologic Malignancies**
  - Tuesday, Aug. 10, 2010 10am-12pm – COMPLETED
- **Concepts and Clinical Applications**
  - Wednesday, Aug. 11, 2010 – COMPLETED
- **Psychiatry II: Antipsychotics**
  - Tuesday, Aug. 24, 2010 10am – 12pm – COMPLETED
- **Oncology I: Solid Tumors**
  - Thursday, Aug. 26, 2010 10 am – 12 pm – COMPLETED
- **Cardiology I: Warfarin and Statins**
  - Tuesday, Sept. 21, 2010 10am – 12 pm – COMPLETED
- **Cardiology II: Clopidogrel and Beta Blockers**
  - Thursday, Sept. 23, 2010 10 am – 12 pm – COMPLETED
- **Economic Issues**
  - Tuesday, Oct. 12, 2010 9:30 am – 11:30 am – COMPLETED

Survey Instruments: Evaluation

- Faculty trainers will complete a Post-Training Survey
  - Evaluate knowledge, attitudes, and self-efficacy
- All survey materials will be mailed after completion of all webinars in November 2010

Webinar Dates
(all times are PST)

- **Psychiatry I: Depression**
  - Thursday, Oct. 21, 2010 10am – 12pm
- **Asthma**
  - Tuesday, Nov. 2, 2010 10am – 12pm
- **PharmGenEd™ Program Implementation**
  - Thursday, Aug. 12, 2010: 10 am – 12 pm – COMPLETED
  - Thursday, Sept. 9, 2010: 10 am – 12 pm – COMPLETED
- Please register at www.pharmacogenomics.ucsd.edu to download materials prior to the scheduled webinar

Question and Answer Session